Home » Newsletters » BioWorld Science

BioWorld Science

May 1, 1998

View Archived Issues

ANDA filed for IS-5-MN

Company Profile: Metabasis Therapeutics

AxyS Pharmaceuticals' APC-366 shows good antiasthmatic activity in phase IIa trial

Cypress Bioscience: Q1 1998 highlights

New somatostatin analogues with improved stability and distribution characteristics

European patents issued to Lilly for new benzothiophene compounds

Potent calpain inhibitors disclosed by Mitsubishi Chem.

Taisho scientists isolate cell adhesion inhibitors for arthritis, inflammation and asthma

Lymphocyte-stimulating factor and methods of treating or preventing African sleeping sickness

Update on Repligen's angiogenesis inhibitors

Corvas/Schering-Plough HCV protease collaboration extended

Variagenics licenses diagnostic, therapeutic uses of gene discovered at Mayo Foundation

Feasibility of edible vaccine established in humans

Targeted cytotoxic therapy cures breast cancer in mice at nontoxic doses

Genetronics begins phase II trial of electroporation therapy in U.S.

PowderJect reports positive clinical data for erectile dysfunction product

Improved gastrointestinal delivery of heparin with SNAC

YJA-20379, an H+/K+-ATPase inhibitor that inhibits H. pylori

Cheung Laboratories announces name change

ITF-1779: a novel TNF-alpha inhibitor for sepsis and other inflammatory disorders

rhVEGF promotes angiogenesis in underperfused myocardium

Beneficial effects of tolcapone on sleep disturbances in parkinsonian patients

Lamotrigine evaluated for the treatment of childhood autism

LY-300164 suppresses kindling-induced seizures in mice

First clinical results reported for NPS-1506

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...